Navigation Links
How to Enhance Scientific Intuition in Pharmaceutical R&D: the CBCD Highlights a Revolutionary New Technology

Rochester, NY (PRWEB) November 27, 2013

Rational Drug Design, which uses computers in designing new drug entities that bind with specific targets, did not resolve the productivity crisis in pharmaceutical R&D. “The current target based drug design approach is incomplete because most of the drugs developed by structure guided approaches have been shown to have serious toxic side effects.” This is according to a study published on October 14, 2009 in the European Journal of Pharmacology (2).

Furthermore, Jack Scannell, an analyst at Sanford C. Bernstein who covers European pharma said, “Only a minority of the most innovative drugs had their origins in target-based drug discovery; 17 out of 50. And of these 17, two drugs were eventually approved for indications that were entirely different to those that were intended at the start of the target based search.” The article was published on March 28, 2012 on (3).

The problem, however, is not computers. There are definite benefits in computer-aided drug design. But, in rational drug design, computers only process chemical information. They do not process biological information. In rational drug design, computers are a wonderful tool, but they are only as good as the intuition of the scientists that enter the input and interpret the output. The CBCD believes that today, the limiting factor in pharmaceutical R&D, and the cause of the productivity crisis, is the intuition of these scientists.

Let’s quantify intuition with the following measure. An increase in intuition is any increase in the foresight of the scientists. Or, in simple terms, the more scientists can look into the future, the better the scientist’s intuition is. Another example: Take two scientists. The one who says to the other ten years after the fact, “you were right” has less foresight, and less intuition.

Computer Intuition enhances scientific intuition. That is, it increases the scientists’ foresight and helps them make better, more accurate predictions.

“The following is a description of one prospective application of Computer Intuition. In 1995, Frederiksen published a paper entitled: Diagnostic Imaging in Dental Implantology. At the time, Frederiksen was one of the world leading experts on the subject. To test the predictive power of the Computer Intuition analysis, Almog and Heisler from the University of Rochester devised a test. They conducted a Medline search for papers published between 1980 and 1996 using keywords relevant to the subject of diagnostics, imaging, and dental implantology. The search identified 34 papers. The content of these papers was analyzed with Computer Intuition. The analysis produced three ideas. Two ideas were identical to the main conclusions described in Frederiksen’s paper. This, by itself, was an impressive achievement. By using Computer Intuition, Almog and Heisler duplicated the results of a world leading expert quickly and inexpensively. However, while it took Frederiksen decades to build his expertise, Almog and Heisler acquired similar expertise within weeks. The third idea suggested a new technology. This technology was not mentioned in Frederiksen’s paper. The three ideas were published in 1997 (1).”

"Computer Intuition is a profound departure from previous drug discovery methods. Rational drug design, or computational R&D, is a system that works in the chemical sphere. They process chemical information. In contrast, CI operates in the biological sphere." – Greg Bennett, CBCD

The CBCD invites pharmaceutical executives to contact the Center at info(at)cbcd(dot)net or phone 585-250-9999 to learn how Computer Intuition can be utilized to enhance and further their firms’ R&D goals.


(1)     Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.

(2)     Rational drug design. Published on October 14, 2009.

(3)     The Drug Industry's Blind Alley. Published on March 28, 2012.

The Center for the Biology of Chronic Disease (CBCD, is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Blocked holes can enhance rather than stop light going through
2. Auxilium Announces Appointments to Enhance Leadership Team
3. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
4. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
5. McLean Report on nanotechnology that may enhance medication delivery and improve MRI performance
6. Bio-inspired polymer synthesis enhances structure control
7. BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research
8. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
9. Synteract Unveils New Branding at DIA 2012 to Support Enhanced Commercial Strategy
10. Spiral Flow(TM) Grafts Enhance Patient Outcomes - New Paper Published in the Prestigious Annals of Vascular Surgery
11. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
Breaking Biology News(10 mins):